Vosoritide
Also referenced as: Voxzogo
A C-type natriuretic peptide analogue used to increase growth in children with achondroplasia.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Voxzogo has FDA accelerated approval to increase linear growth in children with achondroplasia and open epiphyses; the historical age-5 lower limit is outdated.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A C-type natriuretic peptide analogue used to increase growth in children with achondroplasia.
Voxzogo has FDA accelerated approval to increase linear growth in children with achondroplasia and open epiphyses; the historical age-5 lower limit is outdated.
Open growth plates and the specific disease indication matter; approval does not establish general height enhancement.
Why It's Being Studied
- Achondroplasia
- Growth plate signalling
Mechanism of Action
NPR-B activation counteracts downstream FGFR3 signalling in growth plates.
NPR-B activation counteracts downstream FGFR3 signalling in growth plates. Open growth plates and the specific disease indication matter; approval does not establish general height enhancement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Achondroplasia
- Growth plate signalling
- Subcutaneous approved medicine
Evidence Summary
Human growth-velocity evidence supports accelerated approval; improvement in linear growth is not proof that all achondroplasia complications are prevented.
Higher tiers carry more weight. Filled tiers have evidence for Vosoritide; tap to read it.
- Human growth-velocity evidence supports accelerated approval; improvement in linear growth is not proof that all achondroplasia complications are prevented.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human growth-velocity evidence supports accelerated approval; improvement in linear growth is not proof that all achondroplasia complications are prevented.
Reported Adverse Events in Research
- Hypotension and injection-site reactions are key adverse effects.
Limitations of Current Evidence
- Open growth plates and the specific disease indication matter; approval does not establish general height enhancement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Vosoritide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Vosoritide — prescribing label